News from the CGRP Forum
Galcanezumab has significant impact on episodic but not chronic cluster headache
A Phase 3 trial of galcanezumab in patients with episodic cluster headache has met its primary endpoint. Galcanezumab significantly reduced weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period (-8.7 for galcanezumab vs -5.2 for placebo, p=0.036).
Read the full report here »